fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

Category Archives: pharmaceuticals

Groups Urge Congress to Protect Seniors from Rising Drug Prices

November 13, 2018 | FAH Policy Blog Team

Category: Medicare, Pharmaceuticals

The Federation of American Hospitals joined 16 other groups in sending a letter to Congressional leaders today urging them to preserve the actions taken in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices during the upcoming lame duck session of Congress.

Read More »

FAH Leader Comments on the Trump Administration’s Proposal To Change Medicare Drug Prices

October 25, 2018 | Chip Kahn

Category: Financing, Medicare, Pharmaceuticals

We agree with the President that it is time to reduce the drug tab for Americans, but actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.

Read More »

FAH Comments on 2019 OPPS Proposed Rule

September 24, 2018 | FAH Policy Blog Team

Category: Financing, Pharmaceuticals, Quality

This afternoon FAH filed comments with CMS regarding the 2019 Hospital Outpatient Prospective Payment System (OPPS) proposed rule.

Read More »

FAH Comments on Senators Grassley and Durbin Drug Pricing Amendment

August 21, 2018 | FAH Policy Blog Team

Category: FAH News, Legislation, Pharmaceuticals

Rising and excessive drug prices threaten patient access to the drugs they need and can undermine the care physicians see as necessary for patients. The Grassley-Durbin amendment (#3787) would take a great leap forward in providing consumers useful information on drug prices that could help them buy smart. And, the public display of prices could put a spotlight on those high prices and bring them down.

Read More »